Arizona State Retirement System Buys Shares of 12,894 Replimune Group, Inc. (NASDAQ:REPL)

Arizona State Retirement System bought a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL) in the 4th quarter, Holdings Channel reports. The institutional investor bought 12,894 shares of the company’s stock, valued at approximately $156,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Braidwell LP boosted its stake in Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after purchasing an additional 2,057,460 shares during the period. State Street Corp boosted its stake in Replimune Group by 102.1% in the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after purchasing an additional 1,182,181 shares during the period. Baker BROS. Advisors LP boosted its stake in Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after purchasing an additional 1,000,000 shares during the period. Parkman Healthcare Partners LLC boosted its stake in Replimune Group by 45.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock worth $8,371,000 after purchasing an additional 238,747 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after purchasing an additional 217,308 shares during the period. Institutional investors own 92.53% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Jefferies Financial Group increased their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. HC Wainwright increased their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Finally, BMO Capital Markets increased their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $19.43.

Replimune Group Trading Down 1.8 %

Shares of NASDAQ:REPL opened at $11.65 on Monday. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $17.00. The company has a market capitalization of $897.22 million, a P/E ratio of -3.79 and a beta of 1.30. The company has a 50-day simple moving average of $12.66 and a 200 day simple moving average of $12.13. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Sell-side analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.